Syndax Pharmaceuticals Intrinsic Value – Pierre Legault Sells 24000 Shares of Syndax Pharmaceuticals, Stock
January 28, 2023
Trending News ☀️
Syndax Pharmaceuticals Intrinsic Value – Syndax Pharmaceuticals ($NASDAQ:SNDX), Inc. is a biopharmaceutical company focused on the development and commercialization of therapies to improve the treatment of cancer. The company’s product portfolio includes a variety of different molecules, including immuno-oncology therapies as well as small molecule and antibody-drug conjugate treatments. Recently, it was announced that Pierre Legault had sold 24000 shares of Syndax Pharmaceuticals, Inc. stock. Although the exact details of his sale have not been disclosed, it is likely that Pierre Legault sold his shares in order to diversify his investments. The sale of these shares is not expected to have a major effect on the company’s short-term financial position.
However, it could have implications for the company’s long-term prospects. For example, if other shareholders decide to follow Pierre Legault’s lead and sell their shares, this could have a negative impact on the company’s stock price.
Additionally, it could cause investors to become more cautious when considering investing in Syndax Pharmaceuticals, Inc. However, it is important to keep an eye on the stock market to see if other investors follow suit and decide to sell their shares as well. This could have a significant impact on the company’s stock price and investor sentiment going forward.
Stock Price
Right now news coverage of the company is mostly positive. On Tuesday, Syndax Pharmaceuticals stock opened at $26.4 and closed at $26.5, up by 0.6% from prior closing price of 26.3. This is a testament to their successful operations and impressive research and development efforts. The company has been able to consistently outperform its competitors in the healthcare sector and has gained a lot of traction in the past few years. The company is currently focused on developing novel drugs and therapies that can help treat cancer and other diseases. The company’s pipeline of drugs is extensive and it has been able to secure numerous partnerships with leading healthcare companies.
This has allowed them to gain access to valuable resources and technology that can help them move forward with their research and development efforts. The sale of 24000 shares of Syndax Pharmaceuticals stock by Pierre Legault comes as a surprise to many investors, but it is not necessarily a bad sign for the company. Legault’s decision could be based on a variety of factors and it is possible that he believes that the stock has reached its peak or that he is looking for other investments. Whatever his reasoning, it is clear that the market still has faith in the company’s future prospects. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Syndax Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 126.58 | -13.95 | -11.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Syndax Pharmaceuticals. More…
| Operations | Investing | Financing |
| -10.07 | -108.52 | 118.53 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Syndax Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 359.69 | 21.59 | 5.62 |
Key Ratios Snapshot
Some of the financial key ratios for Syndax Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 337.0% | – | -8.6% |
| FCF Margin | ROE | ROA |
| -8.1% | -1.9% | -1.9% |
VI Analysis – Syndax Pharmaceuticals Intrinsic Value
SYNDAX PHARMACEUTICALS is a company with strong potential for the long-term, as reflected in its fundamentals. Investors can get a good look at this potential with the help of the VI app, which provides a simple analysis of the company’s financials. According to the app’s calculations, the fair value of SYNDAX PHARMACEUTICALS shares is $421.9. Yet, despite this promising valuation, the stock is currently trading at $26.5, undervalued by a staggering 94%. This presents a great opportunity for investors looking to take advantage of a significant discount on the stock. Investors should be aware that SYNDAX PHARMACEUTICALS is an early-stage company, and therefore carries a higher degree of risk than more established companies. However, the company’s strong fundamentals suggest that it has a good chance of success in the long-term. If investors are willing to take on the additional risk associated with early-stage companies, there is a huge potential for gains from investing in SYNDAX PHARMACEUTICALS. In conclusion, SYNDAX PHARMACEUTICALS is a company with great potential for long-term investors. Thanks to the VI app, investors can easily analyze the company’s fundamentals and make an informed decision about whether or not to invest. As of now, SYNDAX PHARMACEUTICALS is trading at a significant discount – presenting a huge opportunity for those willing to take on the additional risk associated with early-stage companies. More…
VI Peers
The biopharmaceutical industry is highly competitive, with companies vying for market share in the development and commercialization of innovative therapies. The company’s main competitors are Fate Therapeutics Inc, Arvinas Inc, and Mirati Therapeutics Inc. All three companies are engaged in the development of cancer therapies, with each company having its own proprietary technology and product pipeline.
– Fate Therapeutics Inc ($NASDAQ:FATE)
Fate Therapeutics is a biopharmaceutical company that develops immunotherapies for cancer and other diseases. The company’s immunotherapies are based on its proprietary platform of induced pluripotent stem cells (iPSCs). Fate Therapeutics’ iPSC platform allows the company to generate fully differentiated, functional immune cells from a patient’s own cells. These immune cells can then be used to treat the patient’s disease. The company’s lead product candidates are FT516, an iPSC-derived natural killer cell therapy, and FT767, an iPSC-derived T cell therapy. Fate Therapeutics is also developing FT819, an iPSC-derived myeloid cell therapy.
– Arvinas Inc ($NASDAQ:ARVN)
Arvinas Inc is a pharmaceutical company that focuses on the development of treatments for cancer and other diseases. The company has a market cap of 2.35B as of 2022 and a Return on Equity of -20.23%. Arvinas was founded in 2013 and is headquartered in New Haven, Connecticut.
– Mirati Therapeutics Inc ($NASDAQ:MRTX)
Mirati Therapeutics Inc is a biopharmaceutical company that focuses on the development of novel small molecule therapeutics to treat cancer. The company’s market cap as of 2022 is 3.7B and its ROE is -33.77%. The company’s main products are targeted cancer therapies, which are designed to selectively target and kill cancer cells while sparing normal cells.
Summary
While the current news coverage of the company is mostly positive, it is important to consider the potential risks and rewards of investing in the company. Investors should analyze the company’s financials, including its balance sheet and income statement, and research its industry and competitive landscape. It is also important to consider the potential impact of any upcoming clinical trials and drug approvals, as well as the company’s history of product development and marketing. Finally, investors should always be sure to adhere to their own risk tolerance when making any investment decision.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
